Xiao YM, Yang SK, Wang Y, Mao D, Duan FL, Zhou SK. Retroperitoneal laparoscopic partial nephrectomy for unilateral synchronous multifocal renal carcinoma with different pathological types: A case report. World J Clin Cases 2021; 9(23): 6879-6885 [PMID: 34447838 DOI: 10.12998/wjcc.v9.i23.6879]
Corresponding Author of This Article
Shu-Kui Zhou, MD, PhD, Doctor, Surgical Oncologist, Department of Urology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55 Section 4, Renmin South Road, Wuhou District, Chengdu 610041, Sichuan Province, China. jackten@aliyun.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 16, 2021; 9(23): 6879-6885 Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6879
Retroperitoneal laparoscopic partial nephrectomy for unilateral synchronous multifocal renal carcinoma with different pathological types: A case report
Ying-Ming Xiao, Sheng-Ke Yang, Dun Mao, Shu-Kui Zhou, Department of Urology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, Sichuan Province, China
Ying Wang, Department of Urology, Affiliated Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
Fang-Lei Duan, Department of Pathology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, Sichuan Province, China
Author contributions: Zhou SK designed the study and revised the manuscript critically for important intellectual content; Xiao YM, Yang SK, and Wang Y collected and analyzed the clinical data, reviewed the literature, and drafted the manuscript; Duan FL was responsible for the pathological diagnosis; Mao D participated in the collection of clinical data; All authors have read and approved the final manuscript.
Supported bythe Incubation Project of Outstanding Young Scientist Fund of Sichuan Province, No. 2019JDJQ0039; the Key Research Foundation of Sichuan provincial health commission, No. 19ZD015; and the Interdisciplinary Program of Shanghai Jiao Tong University, No. YG2021QN102.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors have no financial interests or conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Kui Zhou, MD, PhD, Doctor, Surgical Oncologist, Department of Urology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55 Section 4, Renmin South Road, Wuhou District, Chengdu 610041, Sichuan Province, China. jackten@aliyun.com
Received: April 17, 2021 Peer-review started: April 17, 2021 First decision: May 10, 2021 Revised: May 15, 2021 Accepted: June 28, 2021 Article in press: June 28, 2021 Published online: August 16, 2021 Processing time: 110 Days and 4.7 Hours
Abstract
BACKGROUND
The majority of renal cell carcinomas are single lesions; unilateral synchronous multifocal renal carcinoma (USMRC) is rarely reported and poses a treatment challenge for urological oncologists.
CASE SUMMARY
A 56-year-old man was hospitalized for pain and discomfort in the right kidney area for 6 d. Contrast-enhanced computed tomography demonstrated cT1a renal tumors at the lower pole of the right kidney and a cT1b renal tumor at the middle dorsal portion of the right kidney. The patient underwent retroperitoneal laparoscopic partial nephrectomy (RLPN). There were no complications peri-operatively. Histopathology revealed a low-grade, pathologic stage T1a (pT1a), clear cell renal cell carcinoma at the lower pole of the right kidney and a pT1b, chromophobe renal cell carcinoma at the middle dorsal portion of the right kidney. No tumor bed recurrence or metastasis was observed on imaging and his renal function remained stable during the 12-mo follow-up period.
CONCLUSION
RLPN is a safe, effective, and feasible for the management of USMRC, which can obtain equivalent oncological results with optimal renal function preservation.
Core Tip: Unilateral synchronous multifocal renal carcinoma (USMRC) is defined as having more than two malignant tumors with a spacing ≥ 1 cm in one kidney. USMRC is rarely reported and nephron-sparing surgery for USMRC is difficult. We describe a patient with USMRC who underwent retroperitoneal laparoscopic partial nephrectomy (RLPN). There were no complications peri-operatively. Histopathology revealed clear cell renal cell carcinoma at the lower pole of the right kidney and chromophobe renal cell carcinoma at the middle dorsal portion of the right kidney. No tumor bed recurrence or metastasis was observed on imaging and his renal function remained stable during the 12-mo follow-up. Thus, RLPN is safe, effective, and feasible for the management of USMRC.
